Koray ELTER, Tijen Alev ÖZAY, Elif ERGİN, Murat Hakan ÖZÖRNEK

Serum Oestradiol Pattern during Coasting is Different in Antagonist Cycles Compared with Long Agonist Cycles in In Vitro Fertilisation

.Background: GnRH agonists and antagonists have different mechanism of action, and therefore serum estradiol levels might differ during coasting in IVF.Aims: To compare the change in serum oestradiol levels after withholding the gonadotropins for coasting between long agonist and antagonist cycles.Study Design: Retrospective study.Methods: Antagonist and long agonist cycles, in which coasting was performed, were analysed in this retrospective analysis. Antagonist cycles (n=50)were compared with long agonist cycles (n=52) with respect to daily serum oestradiol levels following withholding of gonadotropins.Results: The pattern of change in serum oestradiol was different between groups; it increased on the first day by 11.2% and decreased thereafter on thesecond and third days in the agonist group. However, it began to decrease from the first day in the antagonist group. Therefore, peak serum oestradiollevels were significantly higher in the agonist group than in the antagonist group (mean±standard deviation; 5798±1748 vs 5104±1351 pg/mL). The durationof coasting was shorter in the antagonist group compared with that in the agonist group (mean±standard deviation; 2.60±1.40 vs 1.96±0.88 days).Conclusion: Serum oestradiol pattern during coasting is different in antagonist cycles compared with long agonist cycles in in vitro fertilisation.

PDF

___

1. Elter K, Nelson LR. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer:a review. Obstet Gynecol Surv 2001;56:576-88. [CrossRef]
2. Diedrich K, Diedrich C, Santos E, Bauer O, Zoll C, al-Hasani S, et al. Suppression of endogenous LH increase in ovarian stimulation with the GnRH antagonist Cetrorelix. Geburtshilfe Frauenheilkd 1994;54:237-40. [CrossRef]
3. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984;2:1284-5. [CrossRef]
4. Lin Y, Kahn JA, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Hum Reprod 1999;14:885-8. [CrossRef]
5. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG:results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526-31. [CrossRef]
6. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-20. [CrossRef]
7. Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reprod Biomed Online 2003;7:185-9. [CrossRef]
8. Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, et al. Human ovarian steroid secretion in vivo:effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 2001;16:2533-9. [CrossRef]
9. Abdallah R, Kligman I, Davis O, Rosenwaks Z. Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med 2010;28:486-92. [CrossRef]
10. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome:an update review. Obstet Gynecol Surv 1989;44:430-40. [CrossRef]
11. Elter K, Ozay AT, Ergin E, Ozornek H. Serum estradiol pattern during coasting is different in antagonist cycles compared to long agonist cycles in in vitro fertilization. 14th World Congress on in Vitro Fertilization & 3rd World Congress on in Vitro Maturation, September 15 - 19, 2007, Montreal, Canada. Abstract Book p. 130 [Abstract P-1258].
12. Egbase PE, Al Sharhan M, Berlingieri P, Grudzinskas JG. Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment. Hum Reprod 2000;15:2082-6. [CrossRef]
13. Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999;84:228-32. [CrossRef]
14. Gustofson RL, Bush MR, Segars JH, Larsen FW. The novel use of ganirelix to rescue hyperresponding stimulation cycles from cancellation in patients treated with microdose lupron. 60th Annual Meeting of the ASRM. October 16 - 20, 2004, Philadelphia, Pennsylvania, USA. Fertil Steril 82, Suppl. 2, S32-S33.
15. Gustofson RL, Larsen FW, Bush MR, Segars JH. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome. Fertil Steril 2006;85:251-4. [CrossRef]
16. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 2006;21:2830-7. [CrossRef]
17. The Practice Committee of the ASRM. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90:S188-93. [CrossRef]
18. Abdalla H, Nicopoullos JD. The effect of duration of coasting and estradiol drop on the outcome of assisted reproduction: 13 years of experience in 1,068 coasted cycles to prevent ovarian hyperstimulation. Fertil Steril 2010;94:1757-63. [CrossRef]
19. Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005;20:3167-72. [CrossRef]
20. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002;17:310-3. [CrossRef]
21. Isaza V, Garcia-Velasco JA, Aragones M, Remohi J, Simon C, Pellicer A. Oocyte and embryo quality after coasting:the experience from oocyte donation. Hum Reprod 2002;17:1777-82. [CrossRef]
22. Waldenstrom U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients:a multicentre study. Hum Reprod 1999;14:294-7. [CrossRef]